OTC Markets OTCQX - Delayed Quote USD
Orgenesis Inc. (ORGS)
2.4900
+0.2800
+(12.67%)
At close: April 23 at 4:00:00 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
899
530
36,025
35,502
7,652
Cost of Revenue
1,777
6,255
5,133
28,889
31,099
Gross Profit
-878
-5,725
30,892
6,613
-23,447
Operating Expense
46,685
49,166
38,433
21,135
72,334
Operating Income
-47,563
-54,891
-7,541
-14,522
-95,781
Net Non Operating Interest Income Expense
-2,869
-2,174
-1,826
-718
-901
Other Income Expense
15,084
-7,380
-2,593
-2,711
-54
Pretax Income
-35,348
-64,445
-11,960
-17,951
-96,736
Tax Provision
-88
473
209
108
-1,609
Net Income Common Stockholders
-34,412
-55,361
-14,889
-18,053
6,270
Diluted NI Available to Com Stockholders
-34,412
-55,361
-14,889
-18,053
6,270
Basic EPS
-24.46
-19.10
-5.90
-7.40
2.90
Diluted EPS
-24.46
-19.10
-5.90
-7.40
2.90
Basic Average Shares
3,703.5420
2,900.7860
2,509.6280
2,427.3650
2,132.0310
Diluted Average Shares
3,703.5420
2,900.7860
2,509.6280
2,427.3650
2,132.0310
Total Operating Income as Reported
-28,309
-53,636
-10,110
-16,800
-95,785
Rent Expense Supplemental
309
161
199
249
407
Total Expenses
48,462
55,421
43,566
50,024
103,433
Net Income from Continuing & Discontinued Operation
-34,412
-55,361
-14,889
-18,053
1,110
Normalized Income
-49,753.7110
-50,107.5000
-13,895.1800
-16,272.5300
-94,438.6613
Interest Expense
2,901
2,167
1,824
943
1,254
Net Interest Income
-2,869
-2,174
-1,826
-718
-901
EBIT
-32,447
-62,278
-10,136
-17,008
-95,482
EBITDA
-30,628
-60,718
-8,158
-15,144
-94,047
Reconciled Cost of Revenue
774
5,462
4,116
28,015
30,243
Reconciled Depreciation
1,819
1,560
1,978
1,864
1,435
Net Income from Continuing Operation Net Minority Interest
-34,412
-55,361
-14,889
-18,053
-94,596
Total Unusual Items Excluding Goodwill
15,380
-6,650
-1,258
-2,439
-160
Total Unusual Items
15,380
-6,650
-1,258
-2,439
-160
Normalized EBITDA
-46,008
-54,068
-6,900
-12,705
-93,887
Tax Rate for Calcs
0
0.0002
0.0002
0.0003
0
Tax Effect of Unusual Items
38.2890
-1,396.5000
-264.1800
-658.5300
-2.6613
12/31/2020 - 3/13/2012
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
PYPD PolyPid Ltd.
2.7500
+0.36%
ISCO International Stem Cell Corporation
0.1100
0.00%
CYCCP Cyclacel Pharmaceuticals, Inc.
5.0000
+1.42%
ANEB Anebulo Pharmaceuticals, Inc.
0.9700
0.00%
BVAXF BioVaxys Technology Corp.
0.0286
-0.69%
XTLB XTL Biopharmaceuticals Ltd.
1.2150
-7.25%
DYAI Dyadic International, Inc.
1.2100
-2.42%
ARMP Armata Pharmaceuticals, Inc.
1.3200
+1.08%
OGEN Oragenics, Inc.
0.1940
+3.74%
PMCB PharmaCyte Biotech, Inc.
1.1900
+2.59%